7 studies were found.

1.		No longer recruiting	Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Conditions: Previously Treated Myelodysplastic Syndrome; de novo myelodysplastic syndrome; refractory anemia with excess blasts in transformation; ...
2.		Recruiting	Celecoxib and/or Selenium in Treating Patients With Adenomatous Colorectal Polyps Conditions: Colon Cancer; Rectal Cancer
3.		No longer recruiting	Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Conditions: actinic keratosis; squamous cell carcinoma of the skin; prevention of skin cancer; basal cell carcinoma of the skin
4.		Not yet recruiting	Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants Condition: unspecified adult solid tumor, protocol specific
5.		No longer recruiting	High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer Conditions: stage IIIB breast cancer; Drug Toxicity; stage IIIA breast cancer; stage IV breast cancer; recurrent breast cancer
6.		No longer recruiting	Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer Conditions: Leukemia; Lymphoma; Multiple Myeloma
7.		No longer recruiting	Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer Conditions: stage II prostate cancer; stage III prostate cancer; stage I prostate cancer; adenocarcinoma of the prostate; radiation toxicity